Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma
NCT04880434Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Apr 2021
- Primary completion
- Jun 2025
- Countries
- 6
01
Overview
A Phase 2 trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Kite Pharma. Started Apr 2021; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04880434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880434.